

Barbara Spanò<sup>1</sup>, Ornella Argento<sup>2</sup>, Valerio Pisani<sup>2</sup>, Chiara Incerti<sup>2</sup>, Marco Bozzali<sup>1</sup>, Carlo Caltagirone<sup>3,4</sup>, Ugo Nocentini<sup>2,3</sup>.

[1] Neuroimaging Laboratory, Santa Lucia Foundation, IRCCS, Rome, Italy, --- [2] Neurology and Neurorehabilitation Unit, Santa Lucia Foundation, IRCCS, Rome, Italy. [3] Department of Neuroscience, University of Rome "Tor Vergata", Rome, Italy, --- [4] Department of Clinical and Behavioural Neurology, Santa Lucia Foundation, IRCCS, Rome, Italy. [b.spano@hsantalucia.it](mailto:b.spano@hsantalucia.it) --- [o.argo@hsantalucia.it](mailto:o.argo@hsantalucia.it)

## Introduction:

CMI correlates have been widely investigated in patients with MS. Discrepancies in methods, CMI paradigms and samples, led to an incomplete interpretation of this process [1]. This study tried to overpass these limits by comparing CMI in patients with MS and HC under different cognitive conditions. About brain structural involvement we focused on GM.

## Methods and Results:

### Participant characteristics:

	HC	MS
<b>N</b>	<b>10</b>	<b>15</b>
<b>Age</b>	<b>39.0 (11.8)</b>	<b>44.4 (6.3)</b>
<b>Sex (F/M)</b>	<b>6/4</b>	<b>8/7</b>
<b>Education (years)</b>	<b>13.8 (3.1)</b>	<b>12.5 (3.3)</b>
<b>MS phenotype (RR/SP)</b>	-	<b>15/5</b>
<b>EDSS</b>	-	<b>3.5 (1.0-6.5)</b>
<b>DD</b>	-	<b>11.92 (9.9)</b>

For Age, DD, Education, mean (SD) are shown. For EDSS, median (range) are shown.

### DT paradigm:

• DT was composed by three two-minutes trials in which subjects were asked to walk fast along an established route in a quite hallway: in trial-N subjects only had to walk, in trial-C they had to backward counting from 100 by subtracting 3, in trial-W they had to perform a semantic Word List Generation task. Covered distance, correct scores, and errors were counted for each trial.

### MR acquisition @ 3T (Philips Achieva):

- FLAIR & Dual-echo scans for T2L identification
- T1-3D weighted MPRAGE




### MRI DATA preprocessing:

- MPRAGE data were processed according to VBM8 protocol [2,3], using SPM8 toolbox ([www.fil.ion.ucl.ac.uk/spm/](http://www.fil.ion.ucl.ac.uk/spm/)), to produce a GM probability map in Montreal Neurological Institute (MNI) coordinates for each subject.

### DT Results:


- Preliminary data show that both groups decreased their walking performance from trial-N to -C and -W; patients with MS showed significantly greater decrease than HC in both interference conditions. No difference in cognitive performances between patients with MS and HC was found. The covered distance in the trial-N were then converted into z-scores by using the mean and the SD of HC. Patients with MS were then divided into high performers (Hp>1.5 SD) and low performers (Lp<1.5 SD).

### MRI Statistical Analysis:




GM voxel-wise between-group comparison (HC, HpMS, LpMS) was carried out in SPM8 ([www.fil.ion.ucl.ac.uk/spm/](http://www.fil.ion.ucl.ac.uk/spm/)), adjusting for age and sex.

### DT Results



### MRI GM Results: HC > LpMS (p<0.05 FWE-cluster-level-corrected)



## Discussion and Conclusions:

Results show that CMI also exists in HC, but is significantly more evident in patients with MS. In both groups, motor performance seems to be disadvantaged more than cognitive one independently from task condition. MRI data suggest that patients with MS, who show this disadvantage, have also bilateral GM loss in thalami. Further analysis are ongoing in order to explain structure/performance relationships.

### References:

- [1] Leone C, Patti F, Feys P. Measuring the cost of cognitive-motor dual tasking during walking in multiple sclerosis. *Mult Scler.* 2015;21:123-31.
- [2] Ashburner J, Friston KJ. Unified segmentation. *Neuroimage* 2005; 26:839-851.
- [3] Ashburner J, Friston KJ. Voxel-based morphometry--the methods. *Neuroimage.* 2000;11:805-21. Review.

### Abbreviations:

- CMI= Cognitive-Motor Interference
- DD= disease duration
- DT= Dual-Task
- EDSS= expanded disability status scale
- F/M = female/male
- GM= gray matter
- HC= healthy controls
- HpMS= MS patients with DT high performance
- LpMS= MS patients with DT low performance
- MS= multiple sclerosis
- MPRAGE= magnetization prepared rapid acquisition gradient echo
- MRI= magnetic resonance imaging
- Mt\_W= walking mt performance during DT trial-W
- Mt\_C= walking mt performance during DT trial-C
- RR = relapsing-remitting MS
- SD= standard deviation
- SP= secondary-progressive MS
- T2L= T2-weighted visible lesions
- Trial-C= DT counting trial
- Trial-N = DT neutral trial
- Trial-W= DT word trial